Search Results for:
-
Other News To Note
BioTime Inc., of Alameda, Calif., said at a special meeting on May 21, 2013, its shareholders approved the proposals related to the planned acquisition of stem cell-related assets from Geron Corp., of Menlo Park, Calif., by BioTime's subsidiary, Asterias Biotherapeutics Inc. (See BioWorld Today, April 5, 2013BioWorld Today | Friday, May 24, 2013 -
Clinic Roundup
Cellular Biomedicine Group Inc., of Palo Alto, Calif., achieved 50 percent enrollment of the total projected enrollment required for its Phase I trial to evaluate the safety and preliminary efficacy of tumor stem cell-specific dendritic cell therapy for hepatocellular carcinomaBioWorld Today | Thursday, May 23, 2013 -
Pharma: Other News To Note
GSK is developing a bone marrow-derived stem cell gene therapy through late phase development and has a small number of collaborations in that fieldBioWorld Today | Wednesday, May 22, 2013 -
Pfizer Phase III Failure Hints at ADC Shortcomings
Pfizer also is working with the MD Anderson Cancer Center on a Phase I/II study of the drug prior to stem cell transplant in CD22-positive lymphoid malignanciesBy Marie Powers | BioWorld Today | Wednesday, May 22, 2013 -
Success Reported in Cloning Human Embryonic Stem Cells
Embryonic stem cells have been the subject of so many political fights that it's easy to forget they have also faced formidable scientific obstacles...Embryonic stem cell pioneer Michael West, the co-founder of Geron Corp., of Menlo Park, Calif., and current CEO of BioTime Inc., dryly summarized the approach as "they made Starbucks clones – and it workedBy Anette Breindl and Nuala Moran | BioWorld International | Wednesday, May 22, 2013 -
Australian Stem Cell Centre Ltd.
Bioscan | Tuesday, May 21, 2013 -
Cambridge Stem Cell Institute
Bioscan | Tuesday, May 21, 2013 -
Institute for Stem Cell Research (ISCR)
Bioscan | Tuesday, May 21, 2013 -
International Stem Cell Corp.
Bioscan | Tuesday, May 21, 2013 -
Stem Cell Sciences UK Ltd.
Bioscan | Tuesday, May 21, 2013 -
Stem Cell Therapeutics Corp.
Bioscan | Tuesday, May 21, 2013 -
Clinic Roundup
Neuralstem Inc., of Rockville, Md., presented updated, favorable Phase I data from its spinal cord-derived human neural stem cell (NSI-566) trial in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig 's disease) at the neuro-diabetes special medical symposium in Bucharest, RomaniaBioWorld Today | Tuesday, May 21, 2013 -
Word on the Street
to treat a range of degenerative diseases." – Mary Herbert, professor of reproductive biology at Newcastle University, on the success in cloning human embryonic stem cells from skin cells via somatic cell nuclear transfer "After going over there and seeing how the landscape was changing, it seemed like there was a growing knowledge base around biologics, a lot of which had been focused on biosimilarsBioWorld Insight | Monday, May 20, 2013 -
Week in Review
Stem Cell Therapeutics Corp.'s stock will trade on OTCQX International under the symbol "SCTPFBioWorld Insight | Monday, May 20, 2013 -
Embryonic Stem Cells: Individual Medicine - But With 2 Individuals
And embryonic stem cells have always been the poster child for that fact...More broadly, "many people support embryonic stem cell research only when it uses cells from discarded embryosBy Anette Breindl | BioWorld Insight | Monday, May 20, 2013 -
'JAK'ing Up Myelofibrosis; Sanofi's Phase III Data Solid
In myelofibrosis, up-regulation of blood cell production causes fibrotic tissue to develop in the bone marrow, resulting from acquired mutations targeting hematopoietic stem cellsBy Jennifer Boggs | BioWorld Today | Monday, May 20, 2013 -
Clinic Roundup
Advanced Cell Technology Inc., of Marlborough, Mass., said that the vision of a patient enrolled in a clinical investigation of the company's retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs) has improved from 20/400 to 20/40 following treatment...Stem Cell Therapeutics Corp., of Toronto, said its wholly owned subsidiary Trillium Therapeutics has completed dosing in its Phase I study of TTI-1612 in patients with interstitial cystitis/bladder pain syndrome (ICBioWorld Today | Friday, May 17, 2013 -
Other News To Note
Stem Cell Therapeutics Corp., of Toronto, said the company's stock will trade on OTCQX International under the symbol "SCTPF" starting May 20BioWorld Today | Friday, May 17, 2013 -
Ambit Cuts Price, Ups Shares; $65M IPO to Fund Quizartinib
Bluebird's treatment approach involves the use of stem cells harvested from a patient's bone marrow...LentiD is designed to transduce a patient's hematopoietic stem cells with the lentiviral vector encoding ABCD1 cDNA, the gene that provides transport function in brain cells for clearing up those fatty acidsBy Jennifer Boggs | BioWorld Today | Friday, May 17, 2013 -
Success Reported in Cloning Human Embryonic Stem Cells
Embryonic stem cells have been the subject of so many political fights that it's easy to forget they have also faced formidable scientific obstacles...Embryonic stem cell pioneer Michael West, the co-founder of Geron Corp., of Menlo Park, Calif., and current CEO of BioTime Inc., dryly summarized the approach as "they made Starbucks clones – and it workedBy Anette Breindl and Nuala Moran | BioWorld Today | Thursday, May 16, 2013
Category
Current Filters
- xstem cells
Related Keywords
Categories
- x BioWorld Today (3396)
- x BioWorld International (745)
- x BioWorld Insight (683)
- x Bio Perspectives (140)
- x State of the Industry Report (134)
- x BioWorld Snapshots (48)
- x BioWorld Genomics Review (25)
- x Top 25 Drug Report (23)
- x Biotech Innovations (12)
- x Bioscan (6)
- x BioWorld Phase III Report (3)
- x Market-Leading Biotech Drugs (2)
- x RNAi Report (1)
- x MDD (1)
- x Medical Advances (1)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.